1887

Abstract

Microbial pathogens represent an increasing threat to human health. Although many infections can be successfully treated and cleared, drug resistance is a widespread problem. The existence of subpopulations of ‘tolerant’ cells (where a fraction of the population is able to grow above the population resistance level) may increase the rate of treatment failure; yet, existing methods to measure subpopulation effects are cumbersome. Here we describe , a computational pipeline that analyses photographs of disk diffusion assays to determine the degree of drug susceptibility [the radius of inhibition, (RAD)], and two aspects of subpopulation growth [the fraction of growth (FoG) within the zone of inhibition, (ZOI), and the rate of change in growth from no drug to inhibitory drug concentrations, (SLOPE)]. was used to examine the response of the human fungal pathogen to the antifungal drug fluconazole across different strain backgrounds and growth conditions. Disk diffusion assays performed under Clinical and Laboratory Standards Institute (CLSI) conditions led to more susceptibility and less tolerance than assays performed using rich medium conditions. We also used to quantify the effects of three drugs in combination with fluconazole, finding that all three combinations affected tolerance, with the effect of one drug (doxycycline) being very strain dependent. The three drugs had different effects on susceptibility, with doxycycline generally having no effect, chloroquine generally increasing susceptibility and pyrvinium pamoate generally reducing susceptibility. The ability to simultaneously quantitate different aspects of microbial drug responses will facilitate the study of mechanisms of subpopulation responses in the presence of antimicrobial drugs.

Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.000295
2016-07-01
2021-07-28
Loading full text...

Full text loading...

/deliver/fulltext/micro/162/7/1059.html?itemId=/content/journal/micro/10.1099/mic.0.000295&mimeType=html&fmt=ahah

References

  1. Bednár M. 2000; New formula for calculating antibiotic critical concentration by the disk diffusion method. Med Sci Monitor 6:168–170
    [Google Scholar]
  2. Berghaus L. J., Giguère S., Guldbech K., Warner E., Ugorji U., Berghaus R. D. 2014; Comparison of Etest, disk diffusion, and broth macrodilution for in vitro susceptibility testing of Rhodococcus equi. JCM 53:314–318 [View Article]
    [Google Scholar]
  3. Bigger J. W. 1944; Treatment of staphylococcal infections with penicillin by intermittent sterilisation. Lancet 244:497–500 [View Article]
    [Google Scholar]
  4. Butts A., Krysan D. J. 2012; Antifungal drug discovery: something old and something new. PLoS Pathogens 8:e1002870 [View Article][PubMed]
    [Google Scholar]
  5. Butts A., DiDone L., Koselny K., Baxter B. K., Chabrier-Rosello Y., Wellington M., Krysan D. J. 2013; A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis. Euk Cell 12:278–287 [View Article]
    [Google Scholar]
  6. CLSI 2008; Reference method from broth dilution antifungal susceptibility testing of yeasts. ; Approved standard, 3rd edn. CLSI Document M27-A3 Wayne, PA; Clinical and Laboratory Standards Institute:
  7. Center for Disease Dynamics & Policy 2015 State of the World’s Antibiotics Washington, DC: CDDEP;
    [Google Scholar]
  8. Chen G., Mulla W. A., Kucharavy A., Tsai H. J., Rubinstein B., Conkright J., McCroskey S., Bradford W. D., Weems L. et al. 2015; Targeting the adaptability of heterogeneous aneuploids. Cell 160:771–784 [View Article][PubMed]
    [Google Scholar]
  9. Cohen N. R., Lobritz M. A., Collins J. J. 2013; Microbial persistence and the road to drug resistance. Cell Host Microbe 13:632–642 [View Article][PubMed]
    [Google Scholar]
  10. Coorevits L., Boelens J., Claeys G. 2015; Direct susceptibility testing by disk diffusion on clinical samples: a rapid and accurate tool for antibiotic stewardship. Eur J Clin Microbiol 34:1207–1212 [View Article]
    [Google Scholar]
  11. Cowen L. E., Sanglard D., Calabrese D., Sirjusingh C., Anderson J. B., Kohn L. M. 2000; Evolution of drug resistance in experimental populations of Candida albicans. J Bacteriol 182:1515–1522 [View Article][PubMed]
    [Google Scholar]
  12. Driscoll A. J., Bhat N., Karron R. A., O'Brien K. L., Murdoch D. R. 2012; Disk diffusion bioassays for the detection of antibiotic activity in body fluids: applications for the Pneumonia Etiology Research for Child Health project. Clin Infect Dis 54:S159–S164 [View Article][PubMed]
    [Google Scholar]
  13. Fiori A., Van Dijck P. 2012; Potent synergistic effect of doxycycline with fluconazole against Candida albicans is mediated by interference with iron homeostasis. Antimicrob Agents Chemother 56:3785–3796 [View Article]
    [Google Scholar]
  14. FitzJohn R. G. 2012; Diversitree: comparative phylogenetic analyses of diversification in R. Methods Ecol Evol 3:1084–1092 [View Article]
    [Google Scholar]
  15. Fonzi W. A., Irwin M. Y. 1993; Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717–728[PubMed]
    [Google Scholar]
  16. Fothergill A. W. 2011 ). In Antifungal Susceptibility Testing: Clinical Laboratory and Standards Institute (CLSI) Methods pp 65–74 Totowa, NJ: Humana Press;
    [Google Scholar]
  17. Huys G., D'Haene K., Swings J. 2002; Influence of the culture medium on antibiotic susceptibility testing of food-associated lactic acid bacteria with the agar overlay disc diffusion method. Lett Appl Microbiol 34:402–406 [View Article][PubMed]
    [Google Scholar]
  18. Jensen K. T., Schønheyder H., Gottschau A., Thomsen V. F. 1994; Impact of the agar medium and disc type on disc diffusion susceptibility testing against teicoplanin and vancomycin. APMIS 102:94–102 [View Article][PubMed]
    [Google Scholar]
  19. Lee D.-H., Palsson B. O. 2010; Adaptive evolution of Escherichia coli K-12 MG1655 during growth on a nonnative carbon source, L-1,2-propanediol. Appl Environ Microb 76:4158–4168 [View Article]
    [Google Scholar]
  20. Lewis K. 2010; Persister cells. Annu Rev Microbiol 64:357–372 [View Article][PubMed]
    [Google Scholar]
  21. Li Y., Wan Z., Liu W., Li R. 2015; Synergistic activity of chloroquine with fluconazole against fluconazole-resistant isolates of candida species. Antimicrob Agents Chemother 59:1365–1369 [View Article]
    [Google Scholar]
  22. Liu S., Hou Y., Chen X., Gao Y., Li H., Sun S. 2014; Combination of fluconazole with non-antifungal agents: A promising approach to cope with resistant Candida albicans infections and insight into new antifungal agent discovery. Int J Antimicrob Agents 43:395–402 [View Article]
    [Google Scholar]
  23. Lockhart S. R., Pujol C., Daniels K. J., Miller M. G., Johnson A. D., Pfaller M. A., Soll D. R. 2002; In Candida albicans, white-opaque switchers are homozygous for mating type. Genetics 162:737–745[PubMed]
    [Google Scholar]
  24. Marr K. A., White T. C., van Burik J. A., Bowden R. A. 1997; Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 25:908–910 [View Article][PubMed]
    [Google Scholar]
  25. Matar M. J., Ostrosky-Zeichner L., Paetznick V. L., Rodriguez J. R., Chen E., Rex J. H. 2003; Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother 47:1647–1651 [View Article]
    [Google Scholar]
  26. Odds F. C., Bougnoux M.-E., Shaw D. J., Bain J. M., Davidson A. D., Diogo D., Jacobsen M. D., Lecomte M., Li S.-Y. et al. 2007; Molecular phylogenetics of Candida albicans. Euk Cell 6:1041–1052 [View Article]
    [Google Scholar]
  27. NCCLS 2004 Reference Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline Wayne, PA: NCCLS Document M44-a. National Committee for Clinical Laboratory Standards;
    [Google Scholar]
  28. Pfaller M. A. 2012; Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 125:S3–S13 [View Article][PubMed]
    [Google Scholar]
  29. R Core Team. 2014 R: a Language and Environment for Statistical Computing Austria: Vienna; http://www.R-project.org/
    [Google Scholar]
  30. Redding S., Smith J., Farinacci G., Rinaldi M., Fothergill A., Rhine-Chalberg J., Pfaller M. 1994; Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis 18:240–242 [View Article][PubMed]
    [Google Scholar]
  31. Rex J. H., Pfaller M. A. 2002; Has antifungal susceptibility testing come of age?. Clin Infect Dis 35:982–989 [View Article][PubMed]
    [Google Scholar]
  32. Sanglard D., Kuchler K., Ischer F., Pagani J. L., Monod M., Bille J. 1995; Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. AAC 39:2378–2386 [View Article]
    [Google Scholar]
  33. Sanglard D., Odds F. C. 2002; Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2:73–85 [View Article][PubMed]
    [Google Scholar]
  34. Sharma S. V., Lee D. Y., Li B., Quinlan M. P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L. et al. 2010; A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141:69–80 [View Article][PubMed]
    [Google Scholar]
  35. Siles S. A., Srinivasan A., Pierce C. G., Lopez-Ribot J. L., Ramasubramanian A. K. 2013; High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors. Antimicrob Agents Chemother 57:3681–3687 [View Article]
    [Google Scholar]
  36. Wu W., Lockhart S. R., Pujol C., Srikantha T., Soll D. R. 2007; Heterozygosity of genes on the sex chromosome regulates Candida albicans virulence. Mol Microbiol 64:1587–1604 [View Article][PubMed]
    [Google Scholar]
  37. Zeidler U., Bougnoux M. E., Lupan A., Helynck O., Doyen A., Garcia Z., Sertour N., Clavaud C., Munier-Lehmann H. et al. 2013; Synergy of the antibiotic colistin with echinocandin antifungals in Candida species. J Antimicrob Chemother 68:1285–1296 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/micro/10.1099/mic.0.000295
Loading
/content/journal/micro/10.1099/mic.0.000295
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error